Background and Aims Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with severe, treatment-refractory Crohn’s disease [CD]. The evidence base for AHSCT for CD is limited, with one randomised trial [ASTIC] suggesting benefit. The aim of this study was to evaluate safety and efficacy for patients undergoing AHSCT for CD in Europe, outside the ASTIC trial. Methods We identified 99 patients in the European Society... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- Oxford University Press Publisher's website
- Journal of Crohn's and Colitis Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- European Crohn’s and Colitis Organisation (ECCO)
- Copyright date:
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.